Market closedNon-fractional

Rhythm Pharmaceuticals/RYTM

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

Ticker

RYTM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

226

RYTM Metrics

BasicAdvanced
$2.6B
Market cap
-
P/E ratio
-$4.68
EPS
1.94
Beta
-
Dividend rate
$2.6B
1.94
4.353
3.986
174.814
176.101
-17.43%
-56.20%
-194.69%
26.96
41.9
47.11
-13.65
173.52%
39.22%
1,279.72%
55.40%

What the Analysts think about RYTM

Analyst Ratings

Majority rating from 9 analysts.
Buy

RYTM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-545.55% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$26M
7.02%
Net income
-$141M
239.66%
Profit margin
-545.55%
217.36%

RYTM Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 8.68%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.82
-$0.76
-$0.70
-$2.35
-
Expected
-$0.79
-$0.74
-$0.70
-$2.16
-$0.71
Surprise
3.16%
2.78%
0.29%
8.68%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Rhythm Pharmaceuticals stock?

Rhythm Pharmaceuticals (RYTM) has a market cap of $2.6B as of July 04, 2024.

What is the P/E ratio for Rhythm Pharmaceuticals stock?

The price to earnings (P/E) ratio for Rhythm Pharmaceuticals (RYTM) stock is 0 as of July 04, 2024.

Does Rhythm Pharmaceuticals stock pay dividends?

No, Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Rhythm Pharmaceuticals dividend payment date?

Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders.

What is the beta indicator for Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (RYTM) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Rhythm Pharmaceuticals stock

Buy or sell Rhythm Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing